State of New Jersey Common Pension Fund D Buys 800 Shares of Glaukos Corporation $GKOS

State of New Jersey Common Pension Fund D raised its stake in shares of Glaukos Corporation (NYSE:GKOS) by 4.2% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 19,905 shares of the medical instruments supplier’s stock after acquiring an additional 800 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Glaukos were worth $2,056,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of GKOS. Bessemer Group Inc. lifted its stake in Glaukos by 133.9% during the 1st quarter. Bessemer Group Inc. now owns 276 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 158 shares during the period. First Horizon Advisors Inc. increased its position in shares of Glaukos by 72.9% during the 1st quarter. First Horizon Advisors Inc. now owns 377 shares of the medical instruments supplier’s stock valued at $37,000 after purchasing an additional 159 shares during the last quarter. Park Place Capital Corp increased its position in shares of Glaukos by 68.4% during the 2nd quarter. Park Place Capital Corp now owns 399 shares of the medical instruments supplier’s stock valued at $41,000 after purchasing an additional 162 shares during the last quarter. AlphaQuest LLC increased its position in shares of Glaukos by 5,754.5% during the 2nd quarter. AlphaQuest LLC now owns 644 shares of the medical instruments supplier’s stock valued at $67,000 after purchasing an additional 633 shares during the last quarter. Finally, Bayforest Capital Ltd purchased a new stake in shares of Glaukos during the 1st quarter valued at about $141,000. Institutional investors own 99.04% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Citigroup reduced their price target on shares of Glaukos from $140.00 to $110.00 and set a “buy” rating for the company in a research report on Tuesday, October 7th. William Blair raised shares of Glaukos to a “strong-buy” rating in a research report on Thursday, July 31st. Zacks Research lowered shares of Glaukos from a “strong-buy” rating to a “hold” rating in a research report on Friday, August 15th. Stifel Nicolaus set a $115.00 price target on shares of Glaukos in a research report on Monday. Finally, UBS Group upped their price target on shares of Glaukos from $125.00 to $134.00 and gave the company a “buy” rating in a research report on Thursday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $116.92.

Glaukos Trading Down 0.7%

Glaukos stock opened at $77.27 on Thursday. The firm has a 50 day moving average of $85.58 and a 200 day moving average of $91.60. The firm has a market capitalization of $4.43 billion, a price-to-earnings ratio of -46.83 and a beta of 0.76. Glaukos Corporation has a 12-month low of $73.16 and a 12-month high of $163.71. The company has a current ratio of 5.51, a quick ratio of 4.69 and a debt-to-equity ratio of 0.09.

Glaukos (NYSE:GKOS) last released its earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.11. Glaukos had a negative net margin of 21.43% and a negative return on equity of 8.59%. The firm’s revenue was up 38.1% on a year-over-year basis. During the same period last year, the business posted ($0.28) earnings per share. Glaukos has set its FY 2025 guidance at EPS. As a group, research analysts predict that Glaukos Corporation will post -1.08 earnings per share for the current year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.